Skip to main content
SpringerLink
Log in

Current Guidelines for the Management of Aggressive Non-Hodgkin’s Lymphoma

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The prognosis of aggressive non-Hodgkin’s lymphoma (NHL) has improved greatly during recent years with the use of combination chemotherapy.

Planning the treatment must take into consideration the patient’s age, performance status, histological subtype and disease extent and severity. Recently, a 4-part International Prognostic Index (IPI), based on 5 prognostic factors, has permitted the allocation of patients with NHL in 2 well defined prognostic groups: good prognosis (low and low-intermediate risk) and poor prognosis (intermediate-high and high risk).

Conventional chemotherapy with CHOP (a chemotherapeutic regimen consisting of a combination of cyclophosphamide, doxorubicin, vincristine and prednisone) or other equivalent third-generation regimens may be considered the standard treatment for the good prognosis group. In the poor prognosis group the probability of long term survival is less than 40% with conventional chemotherapy. Therefore, an early intensification with high dose therapy following peripheral stem cell transplantation (PSCT) should be considered in the setting of randomised trials. Localised stage disease, defined as stages I-IE and II-IIE without adverse prognostic factors, has a very good prognosis with a long term survival exceeding 80% using brief conventional chemotherapy regimens plus involved field radiotherapy. Refractory or relapsing patients after the drugs of first choice are given who subsequently respond to salvage chemotherapy should be enrolled for a course of high dose consolidation chemotherapy followed by PSCT. Elderly patients without severe organ dysfunction can take advantage from specifically devised chemotherapy regimens, with a response rate similar to that of younger patients.

However, despite major advances in the treatment of aggressive NHL, additional clinical trials are required to enable the clinician to define the best therapeutic programmes to treat patients with this disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weisenburger DD. Epidemiology of non-Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 1994; 5(9): 19–24

    Article  PubMed  Google Scholar 

  2. National Cancer Institute sponsored study of classification of non-Hodgkins Lymphomas: summary and description of a working formulation of clinical usage. Cancer 1982; 49: 2112–35

    Article  Google Scholar 

  3. Lee Harris N, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood 1994; 84(5): 1361–92

    Google Scholar 

  4. Hiddeman W, Longo DL, Coiffier B, et al. Lymphoma classification: the gap between biology and clinical management is closing. Blood 1996; 88: 4085–9

    Google Scholar 

  5. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive NHL: the international non-Hodgkins lymphoma factors project. N Engl J Med 1993; 329: 987–94

    Article  Google Scholar 

  6. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48. Geneva, Switzerland, WHO, 1979

  7. Carbone PP, Kaplan HS, Musshoff K. Report of the committee on Hodgkin’s disease staging classification. Cancer Res 1971; 31: 1860–1

    PubMed  CAS  Google Scholar 

  8. De Vita Jr TV, Canellos GP, Chabner B, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975; I: 248–50

    Google Scholar 

  9. Coltman Jr CA, Dahlberg S, Jones SE, et al. CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve year Southwest Oncology Group follow-up. In: Skarin AT, editor. Update on treatment for diffuse large B-cell lymphoma. New York: Wiley, 1986: 71–7

    Google Scholar 

  10. Fisher RI, De Vita Jr VT, Hubbard SM, et al. Diffuse aggressive lymphoma: increased survival after alternating flexible sequences of Pro MACE and MOPP chemotherapy. Ann Intern Med 1985; 98: 304–9

    Google Scholar 

  11. Shipp MA, Beow YY, Harrington DP, et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990; 8(1): 84–93

    PubMed  CAS  Google Scholar 

  12. Coleman M, Armitage JO, Gaynor M, et al. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Semin Hematol 1988; 25 (2 Suppl. 2): 22–33

    Google Scholar 

  13. Guglielmi C, Amadori S, Martelli M, et al. The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results. Ann Oncol 1991; 2: 365–71

    PubMed  CAS  Google Scholar 

  14. Miller TP, Dahlberg S, Weick JK, et al. Unfavorable histologies of non-Hodgkins lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group Study. J Clin Oncol 1990; 8(12): 1951–8

    PubMed  CAS  Google Scholar 

  15. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 1985; 102: 596–602

    PubMed  CAS  Google Scholar 

  16. Boyd DB, Coleman M, Papish S, et al. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 1988; 6(3): 425–33

    PubMed  CAS  Google Scholar 

  17. Gordon LI, Harringhton D, Andersen PDJ, et al. Comparison of a second-generation combination chemotherapy regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkins NHL. N Engl J Med 1992; 327: 1342–9

    Article  PubMed  CAS  Google Scholar 

  18. Montserrat E, Garcia-Conde J, Vinolas N, et al. ProMACE-CytaBOM vs CHOP in the treatment of unfavorable lymphomas: a randomized trial [abstract]. Blood 1991; 78: 127A

    Google Scholar 

  19. Cooper IA, Wolf MM, Robertson TI, et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkins lymphoma. J Clin Oncol 1994; 12: 769–78

    PubMed  CAS  Google Scholar 

  20. Mazza P, Zinzani PL, Martelli M, et al. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkins lymphomas. Leuk Lymphoma 1995; 16: 457–63

    Article  PubMed  CAS  Google Scholar 

  21. Sertoli MR, Santini G, Chisesi T, et al. MACOP-B versus Pro-MACE-MOPP in the treatment of advanced diffuse non-Hodgkins lymphoma: results of a prospective randomized trial by the non-Hodgkins lymphoma cooperative study group. J Clin Oncol 1994; 12(7): 1366–74

    PubMed  CAS  Google Scholar 

  22. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (COP) with three intensive chemotherapy regimens for advanced non-Hodgkins lymphoma. N Engl J Med 1993; 328: 1002–6

    Article  PubMed  CAS  Google Scholar 

  23. Zinzani PL, Bendandi M, Martelli M, et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 1996; 14(3): 955–62

    PubMed  CAS  Google Scholar 

  24. Pileri S, Bocchia M, Baroni CD, et al. Anaplastic large cell lymphoma (CD30+/Ki-l+): results of a prospective clinicpathological study of 69 cases. Br J Haematol 1994; 86: 513–23

    Article  PubMed  CAS  Google Scholar 

  25. Bertini M, Orsucci L, Vitolo U, et al. Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. Ann Oncol 1991; 2: 733–7

    PubMed  CAS  Google Scholar 

  26. Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11(12): 2306–13

    PubMed  CAS  Google Scholar 

  27. Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol 1995; 89: 780–9

    Article  PubMed  CAS  Google Scholar 

  28. Haioun C, Gaulard P, Roudot-Thovaral F, et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 1989; 12: 425–9

    Article  PubMed  CAS  Google Scholar 

  29. Todeschini G, Ambrosetti A, Meneghini V, et al. Mediastinal large B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol 1990; 8: 804–8

    PubMed  CAS  Google Scholar 

  30. Lavabre-Bertrand T, Donadio D, Feguex N, et al. A study of 15 cases of primary mediastinal lymphoma of B-cell type. Cancer 1992; 69: 2561–6

    Article  PubMed  CAS  Google Scholar 

  31. Armitage JO, Greer JR, Levine AM, et al. Peripheral T-cell lymphoma. Cancer 1989; 63: 158–63

    Article  PubMed  CAS  Google Scholar 

  32. Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990; 1: 45–50

    PubMed  CAS  Google Scholar 

  33. Coleman CN, Picozzi VJ, Cox RS. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 57–67

    Google Scholar 

  34. Magrath I, Adde M, Shad A. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14(3): 925–34

    PubMed  CAS  Google Scholar 

  35. Fisher RI. CHOP is the current standard for the treatment of high risk patients with diffuse large cell lymphoma [abstract no. 036]. VIth International Conference on Malignant Lymphoma; 1996 Jun 5–8: Lugano. Ann Oncol 1996; 7 Suppl. 3: 12

    Article  Google Scholar 

  36. Coiffier B. Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Ann Oncol 1995; 6: 211–7

    PubMed  CAS  Google Scholar 

  37. Shipp MA, Neuberg D, Janicek M, et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkins lymphoma: a dose finding pilot study. J Clin Oncol 1995; 13(12): 2916–23

    PubMed  CAS  Google Scholar 

  38. Fisher RI. Intermediate and high grade lymphomas. Educational Book 29th annual ASCO meeting; 1993 May 16–18: Orlando, Florida, 125-8

  39. Philip T, Hartmann O, Biron P, et al. High dose therapy and autologous bone marrow transplantation in partial response after front line induction therapy for diffuse NHL. J Clin Oncol 1988; 6: 1118–24

    PubMed  CAS  Google Scholar 

  40. Gulati SC, Shank B, Black P, et al. Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J Clin Oncol 1988; 6: 1303–13

    PubMed  CAS  Google Scholar 

  41. Gribben JG, Goldstone AH, Linch DC, et al. Effectiveness of high dose combination chemotherapy and ABMT for patients with NHL who are still responsive to conventional dose chemotherapy. J Clin Oncol 1989; 7: 1621–9

    PubMed  CAS  Google Scholar 

  42. Verdonck LF, van Putten WLJ, Hagenbeeck A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkins lymphoma. N Engl J Med 1995; 332: 1045–51

    Article  PubMed  CAS  Google Scholar 

  43. Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkins lymphoma with partial response to frontline chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996; 14(2): 534–42

    PubMed  CAS  Google Scholar 

  44. Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkins lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 1994; 12: 2543–51

    PubMed  CAS  Google Scholar 

  45. Gisselbrecht C, Lepage E, Morel P, et al. Short and intensified treatment with autologous stem cell transplantation (ASCT) versus ACVB regimen in poor prognosis aggressive lymphoma: prognostic factors of induction failure [abstract no. 056]. VIth International Conference on Malignant Lymphoma; 1996 Jun 5–8: Lugano. Ann Oncol 1996; 7 Suppl. 3: 18

    Google Scholar 

  46. Gianni AM, Bregni M, Siena S, et al. Is high-dose better that standard-dose chemotherapy as initial treatment of poor-risk large-cell lymphomas? A critical analysis from available randomized trials [abstract no. 037]. VIth International Conference on Malignant Lymphoma; 1996 Jun 5–8: Lugano. Ann Oncol 1996; 7 Suppl. 3: 12

    Google Scholar 

  47. Pettengell R, Crowther D. Haemopoietic growth factor and dose intensity in high grade and intermediate lymphoma. Ann Oncol 1994; 5 Suppl. 2: 133–41

    Article  PubMed  Google Scholar 

  48. Hoppe RT. The role of radiation therapy in the management of the non-Hodgkins lymphomas. Cancer J 1985; 55: 2176–83

    Article  CAS  Google Scholar 

  49. Kaminski MS, Coleman CN, Colby TV, et al. Factors predicting survival in adult with stage I and II large cell lymphoma treated with primary radiation therapy. Ann Intern Med 1986; 104: 747–56

    PubMed  CAS  Google Scholar 

  50. Nissen NI, Ersboll J, Hansen HS, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I–II non-Hodgkins lymphomas. Cancer 1983; 52: 1–7

    Article  PubMed  CAS  Google Scholar 

  51. Miller TP, Jones SE. Initial chemotherapy for clinically localized lymphomas of unfavourable histology. Blood 1984; 62: 413–8

    Google Scholar 

  52. Longo DL, Glatstein E, Duffey PL, et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989; 9: 1295–302

    Google Scholar 

  53. Tondini C, Zanini M, Lombardi F, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkins lymphomas. J Clin Oncol 1993; 4: 720–5

    Google Scholar 

  54. Connors JM, Klimo P, Fairey RN, et al. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 1987; 107: 25–30

    PubMed  CAS  Google Scholar 

  55. De Sanctis V, Giovannini M, Martelli M, et al. Brief chemotherapy followed by involved field radiation therapy for stage I-IE histologically aggressive non-Hodgkins lymphoma [abstract no. 569]. VIth International Conference on Malignant Lymphoma; 1996 Jun 5–8: Lugano. Ann Oncol 1996; 7 Suppl. 3: 154

    Google Scholar 

  56. Miller TP, Dahlberg S, Cassady JR, et al. Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP (8) alone for localized intermediate and high grade non-Hodgkins lymphoma (NHL): a Southwest Oncology Study Group [abstract no. 1257]. Proceedings of the XXXIIth ASCO Meeting; 1996 May 18–21: Philadelphia, PA

  57. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295–305

    PubMed  CAS  Google Scholar 

  58. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269–73

    PubMed  CAS  Google Scholar 

  59. Vose JM, Armitage JO, Dennis D, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkins lymphoma. J Clin Oncol 1988; 6: 1838–44

    PubMed  CAS  Google Scholar 

  60. OReilly S, Klimo P, Connors J, et al. Low dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 1991; 9: 741–7

    CAS  Google Scholar 

  61. OReilly SE, Connos JM, Howdle S, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 1993; 11(11): 2250–7

    CAS  Google Scholar 

  62. Tirelli U, Zagonel D, Errante D, et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkins lymphoma. J Clin Oncol 1992; 10: 228–36

    PubMed  CAS  Google Scholar 

  63. McMaster ML, Johnson DH, Greer JP, et al. A brief duration combination chemotherapy for elderly patients with poorprognosis non-Hodgkins lymphoma. Cancer 1991; 67: 1487–92

    Article  PubMed  CAS  Google Scholar 

  64. Martelli M, Guglielmi C, Coluzzi S, et al. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkins lymphoma. J Clin Oncol 1993; 11: 2362–9

    PubMed  CAS  Google Scholar 

  65. Bastion Y, Blay JY, Divine M, et al. Elderly lymphoma patients have a long survival if treated with a curative intent: a study from the GELA on 453 patients older than 69 years [abstract no. 80]. VI International Conference on Malignant Lymphoma; 1996 Jun 5–8: Lugano. Ann Oncol 1996; 7 Suppl. 3: 24

    Google Scholar 

  66. Velasquez WS, Cabanillas F, Salvador F, et al. Effective therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–22

    PubMed  CAS  Google Scholar 

  67. Cabanillas F, Hagemeister FB, McLaughlin P, et al. Result of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407–12

    PubMed  CAS  Google Scholar 

  68. Zinzani PL, Barbieri E, Visani G, et al. Ifosfamide, epirubicine, and etoposide (IEV) therapy in relapsed and refractory high grade non-Hodgkins lymphoma and Hodgkins disease. Haematologica 1994; 79: 508–12

    PubMed  CAS  Google Scholar 

  69. Philip T, Armitage JO, Spitzer G, et al. High dose therapy and ABMT after failure of conventional chemotherapy in adults with intermediate grade or high grade NHL. N Engl J Med 1987; 316: 1493–8

    Article  PubMed  CAS  Google Scholar 

  70. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkins lymphoma. N Engl J Med 1995; 333: 1540–5

    Article  PubMed  CAS  Google Scholar 

  71. Kessinger A, Armitage JO, Smith DM, et al. High dose therapy and autologous peripheral stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260

    PubMed  CAS  Google Scholar 

  72. Vose JM, Anderson JR, Kessinger A, et al. High-dose chemotherapy and autologous hemapoietic stem-cell transplantation for aggressive non-Hodgkins lymphoma. J Clin Oncol 1993; 11: 1846–51

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haematology, Department of Human Biopathology, Università ‘La Sapienza’, via Benevento 6, 00161, Rome, Italy

    Maurizio Martelli, Vitaliana De Sanctis, Giuseppe Avvisati & Franco Mandelli

Authors
  1. Maurizio Martelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vitaliana De Sanctis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Avvisati
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Franco Mandelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martelli, M., De Sanctis, V., Avvisati, G. et al. Current Guidelines for the Management of Aggressive Non-Hodgkin’s Lymphoma. Drugs 53, 957–972 (1997). https://doi.org/10.2165/00003495-199753060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199753060-00005

Keywords

Search

Navigation